About Savara

Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.

Learn about Savara

Our Science

Our science is fueled by our desire to provide improved treatment options to people living with rare respiratory diseases.

More about our indication

In Development

Our lead product candidate, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

What's in development

Information for Investors

View our press releases, events, presentations, and other important investor information.

Learn more